文献速递抗栓抗凝管理药物不良反应与药物警戒

直接口服抗凝药相关出血的信号检测

Signal detection for bleeding associated with the use of direct oral anticoagulants.
PubMed 文献 · Am J Health Syst Pharm · 2018-05-07

该研究基于FAERS数据库对达比加群、利伐沙班、阿哌沙班、依度沙班和华法林相关出血事件进行定性与定量评价,采用经验贝叶斯方法进行不相称性分析。结果显示DOACs与严重或危及生命的出血之间存在定量信号,共识别出35个EB05>7.5的不良事件术语,涉及40,109份报告。

要点

  • FAERS不相称性分析提示DOACs与严重或危及生命出血存在定量信号
  • DOACs相关EB05>7.5的事件术语共35个,涉及40,109份不良事件报告
  • 华法林相关不良事件共8,729例,常见为出血、血肿和内出血

核心结论

  • FAERS数据库的不相称性分析提示DOACs使用与危及生命或严重出血之间存在定量信号。

研究设计与样本

  • 对截至2017年3月31日涉及达比加群、利伐沙班、阿哌沙班、依度沙班和华法林的出血事件病例报告进行定性与定量评价。
  • 采用基于相对报告率的经验贝叶斯方法对每种DOAC进行不相称性分析,并按MedDRA临床定义进行亚组分析。

主要发现

  • FAERS审查期间识别出35个(任何系统器官分类)DOACs的不相称性评分EB05>7.5的不良事件术语,涉及40,109份不良事件报告。
  • 不相称性评分最高的事件包括心房血栓形成、因子X水平升高、功能障碍性子宫出血、高频消融、心包出血和内出血。
  • EB05最高(>5)的事件包括内出血、出血和大量出血;患者经历数最多的事件为出血(6,881例)、内出血(2,569例)和血肿(1,995例)。
  • 华法林相关不良事件共8,729例,最常见为出血(6,225例)、血肿(2,199例)和内出血(270例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The potential link between serious or life-threatening bleeding and the use of direct oral anticoagulants (DOACs) was evaluated. METHODS: Qualitative and quantitative reviews of case reports of bleeding events involving dabigatran, rivaroxaban, apixaban, edoxaban, and warfarin through March 31, 2017, were performed. A disproportionality analysis was conducted for each DOAC using an empirical Bayesian approach based on the relative reporting rate. Subanalyses were performed to assess (1) bleeding events (including mortality and life-threatening events) associated with DOACs among all adverse-event reports and (2) warfarin-related bleeding events. These analyses were conducted based on clinical definitions from the Medical Dictionary for Regulatory Activities. RESULTS: During the Food and Drug Administration Adverse Event Reporting System (FAERS) review period, 35 adverse-event terms (in any system organ class) with a disproportionality score (EB05) of >7.5 for DOACs were identified; this accounted for 40,109 adverse-event reports. Adverse events with the highest disproportionality scores included atrial thrombosis, increased factor X level, dysfunctional uterine bleeding, high-frequency ablation, pericardial hemorrhage, and internal hemorrhage. Adverse events with the highest EB05 (>5) included internal hemorrhage, hemorrhage, and exsanguination; events with the greatest number of patient experiences included hemorrhage (6,881 events), internal hemorrhage (2,569 events), and hematoma (1,995 events). Warfarin-related events (including death or life-threatening events) were also assessed. A total of 8,729 adverse events were associated with warfarin use. The most common of these included hemorrhage (6,225 events), hematoma (2,199 events), and internal hemorrhage (270 events). CONCLUSION: The disproportionality analysis of the FAERS database suggests a quantitative signal between DOAC use and life-threatening or serious bleeding.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Nathan KT, Conn KM, van Manen RP, et al. Signal detection for bleeding associated with the use of direct oral anticoagulants. Am J Health Syst Pharm. 2018. PMID: 29735612. doi:10.2146/ajhp170529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。